De Western Therapeutics Institute
Basic Information
- Stock Code
- 4576
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Aichi Prefecture
- Establishment Year
- February 1999
- Listing Year
- October 2009
- Official Website
- https://www.dwti.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- GNI Group, Heartseed, Nexera Pharma, Medorex, Peptidream, Ribomic, SanBio, Helios, Fanpep, RenaScience, Qualips, Takara Bio, Japan Tissue Engineering
Overview
De Western Therapeutics Institute is a bio-venture company established in 1999 with headquarters in Nagoya City, Aichi Prefecture, possessing unique drug discovery technology based on protein kinase inhibitors.
Current Situation
De Western Therapeutics Institute has recently recorded consolidated sales of approximately 250 million yen, while posting operating and net losses, emphasizing investments in research and development. Its main business is drug discovery R&D centered on ophthalmology, particularly manufacturing and selling the ROCK inhibitor 'Glanatec' for glaucoma treatment. Joint research and license agreements are underway with multiple pharmaceutical companies. Research is conducted through industry-academia-government collaboration, partnering with Mie University, Rohto Pharmaceutical, and others, with technological development strength as a key advantage. It is also focusing on immune diseases and neuropathic pain drugs, aiming to expand its pipeline diversely. Financially, it is promoting sound capital structure and striving to ensure business sustainability. Moving forward, it positions license-outs expansion and joint development for external funding as growth drivers. In terms of sustainability, it focuses on regional medical support, setting strategic goals of accelerating innovative drug development and financial improvement by 2030. It aims to establish a leading position in the ophthalmic pharmaceuticals sector to meet growing medical needs domestically and internationally.
Trivia
Interesting Facts
- Founder and Representative Director Hideyoshi Hidaka is a medical doctor who served as a visiting professor at Duke University.
- Company name derives from the proprietary Drug Western method developed in-house.
- One of the few domestic companies to successfully commercialize ROCK inhibitors.
- In 2017, made a jointly funded subsidiary with Rohto Pharmaceutical a consolidated subsidiary.
- Representative directors have a history of bribery scandals, drawing attention to management transparency.
- Established a clinical drug discovery research chair in collaboration with Mie University.
- In 2022, transitioned to Tokyo Stock Exchange Growth Market to improve fundraising environment.
- Elite venture with significantly fewer employees compared to peers.
- Glaucoma therapeutic Glanatec is one of the few ROCK inhibitors domestically.
- Acquired ophthalmic surgical adjuvant business from Helios.
- Pioneering niche markets in Japan with diverse ophthalmic products.
- Main related companies include Fanpep, Ribomic, and Medorex.
- Advancing business diversification through multiple license agreements.
- Multiple new drug candidates under joint development in the 2020s.
- Characterized by pipeline diversification among bio pharmaceuticals.
Hidden Connections
- Representative Director and Chairman Hideyoshi Hidaka has a past of receiving prohibited remuneration from multiple companies including Otsuka Pharmaceutical.
- Strengthened technological cooperation system through joint research and investment with Rohto Pharmaceutical.
- Establishment of industry-academia-government clinical drug discovery base with Mie University is a rare case in the industry.
- Aiming for overseas market entry through joint research on glaucoma drugs with U.S. Glaukos Corporation.
- Manufacturing and marketing approval for main product Glanatec demonstrates high technological capability in the industry.
- Holds over 60% of shares in parent company Japan Innovation Pharmaceuticals, making it a consolidated subsidiary.
- Acquired ophthalmic surgical adjuvant business from Helios, expanding business areas.
- Actively pursuing license-outs for multiple ophthalmic and neurological disease drug discovery products.
Future Outlook
Growth Drivers
- Focus on high-growth market specialized in ophthalmic diseases
- Revenue source diversification through joint development and licensing
- Improved R&D efficiency leveraging industry-academia-government collaboration
- Market expansion expectations from increasing domestic and international pharmaceutical demand
- Enhancement of new neurological disease treatment drug pipeline
- Increasing demand for chronic disease therapeutics due to aging society
- Promotion of global partnerships
- New indication expansion through regulatory easing and medical technology evolution
- Improved drug discovery efficiency through digital technology utilization
- Strengthening sustainable development and environmental response
Strategic Goals
- Increase in new drug approvals through innovative drug discovery technology
- Establish leading position in domestic ophthalmic pharmaceuticals market
- Achieve annual consolidated sales of 5 billion yen
- Expand product deployment to global markets
- Achieve ESG standards and promote transparent management
- Expand drug discovery pipeline to diverse disease areas
- Accelerate R&D through strengthened collaboration with pharmaceutical companies
- Build sustainable financial base and secure stable revenue
- Promote research innovation through next-generation technology introduction
- Strengthen medical contributions and information dissemination to regional society
Business Segments
Licensing to Pharmaceutical Companies
- Overview
- Revenue generation through licensing of drug discovery technology and compounds.
- Competitiveness
- High technological capability based on proprietary inhibitor technology
- Customers
-
- Major pharmaceutical companies
- Generic drug manufacturers
- Biotechnology companies
- Research institutions
- Products
-
- ROCK inhibitor technology
- Protein kinase inhibitor candidates
- Licensed drug discovery compounds
Joint Research and Development
- Overview
- Joint promotion of drug discovery research through industry-academia-government collaboration.
- Competitiveness
- Strengthened research foundation as a university-spun venture
- Customers
-
- University research institutions
- Pharmaceutical companies
- Bio ventures
- Products
-
- Ophthalmic drug discovery pipeline
- Neuropathic pain treatment candidates
Ophthalmic Surgical Adjuvant Business
- Overview
- Provision of medical materials for ophthalmic surgical adjuvants.
- Competitiveness
- Product line expansion through business acquisition
- Customers
-
- Ophthalmic medical institutions
- Medical wholesalers
- Products
-
- BBG-containing ophthalmic surgical adjuvant
Competitive Advantage
Strengths
- Proprietary protein kinase inhibitor technology
- Industry-academia-government collaboration R&D system
- Track record in manufacturing and sales of glaucoma therapeutics
- Revenue base from multiple license agreements
- Diversification of drug discovery pipeline
- Rapid decision-making by small elite team
- Strengthened collaboration with Rohto Pharmaceutical
- High expertise in domestic regulatory compliance
- Technology protection through patents
- Regional embedded R&D base
Competitive Advantages
- Advanced technology base unique to university-spun venture
- Pipeline superiority specialized in ophthalmic treatment
- Aggressive promotion of licensing for profitability improvement
- Risk diversification and technology deepening through joint research
- Obtained manufacturing and marketing approval for new ophthalmic therapeutics
- Light-footed organization operation due to small size
- Potential for expansion into diverse disease areas
- Broad network with domestic and international pharmaceutical companies
- Technological superiority secured through IP strategy
- Rapid market response and flexibility
Threats
- Difficulty in market share expansion due to intensifying drug discovery competition
- Financial burden from high R&D costs
- Competition risk from large pharmaceutical companies
- Approval delays due to changes in medical regulations
- Uncertainty in licensing income
- Clinical trial delays due to COVID-19 etc.
- Risk of alternative new drug discovery technologies
- Risk of generics due to patent expiration
- Deteriorating fundraising environment
- Challenges in acquiring and retaining talent
Innovations
2023: License Agreement Signed with Rohto Pharmaceutical for Ophthalmic Therapeutic
- Overview
- Signed license agreement for ophthalmic therapeutic DW-1001 to strengthen product development.
- Impact
- Promotes revenue opportunities expansion and technology synergy improvement
2022: Transition to Tokyo Stock Exchange Growth Market
- Overview
- Achieved strengthened fundraising base through market category change.
- Impact
- Contributes to improved corporate recognition and growth acceleration
2020: Joint Development Agreement Signed with Medorex for Neuropathic Pain Drug
- Overview
- Initiated joint development of neuropathic pain treatment drug (DW-5LBT).
- Impact
- Contributes to new treatment drug pipeline expansion
2020: License Agreement Signed with Wakamoto Pharmaceutical for Ophthalmic Surgical Adjuvant
- Overview
- Acquired usage rights for cataract surgery adjuvant in Japan.
- Impact
- Expands product lineup and strengthens revenue base
2021: Joint Research and License Agreement with Glaukos Corporation for Glaucoma Treatment Product
- Overview
- Advancing technological collaboration with U.S. company on glaucoma therapeutics.
- Impact
- Builds foothold for global market expansion
Sustainability
- Promotion of product development focused on regional medical contributions
- Research facility operations aimed at reducing environmental impact
- Promotion of active roles for female researchers
- Strengthening corporate ethics and transparency
- Social contribution activities to improve medical access